# Virbac Targets Top End of 2026 Growth Guidance After Nine-Month Revenue Reaches €1.17 Billion

- URL: https://stocks.freetheai.org/news/virbac-targets-top-end-of-2026-growth-guidance-after-nine-month-revenue-reaches-a0fa09
- Published: 2026-10-19T15:45:00Z
- Category: earnings; sentiment: bullish; impact: medium
- Symbols: [EURONEXT:VIRP](https://stocks.freetheai.org/symbols/EURONEXT-VIRP)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Animal health company Virbac SA (EURONEXT:VIRP) reported revenue of €1.168 billion for the first nine months of 2026, representing a 7.9% increase at constant exchange rates and scope, or 5.9% on a reported basis. Third-quarter sales reached €400 million, up 8.8% at constant rates, reflecting accelerating momentum across global operations.

Following the nine-month performance, the company now targets the upper end of its full-year 2026 revenue growth guidance range of 5.5% to 7.5% at constant rates and scope. Virbac SA also maintains its profitability target, expecting an adjusted recurring operating income margin of around 17% at constant exchange rates. Organic expansion drove most of the period's growth, with the recent acquisition of Thyronorm contributing approximately 1 percentage point to total revenue.

During the nine-month period, the company generated around €80 million in cash while allocating approximately €125 million toward capital expenditures. Investors will be monitoring fourth-quarter sales execution to confirm whether full-year revenue and profitability meet the targeted top-end expectations.

## Key points

- Nine-month revenue reached €1.168 billion, up 7.9% at constant exchange rates and scope.
- Third-quarter sales rose 8.8% at constant rates to €400 million.
- Full-year 2026 revenue growth is now expected near the upper end of the 5.5% to 7.5% target range.
- Adjusted recurring operating income margin is projected at approximately 17% at constant rates.
- Nine-month cash generation totaled roughly €80 million alongside €125 million in capital expenditures.

## Questions and answers

### What were Virbac SA's nine-month revenue results for 2026?

Virbac SA reported €1.168 billion in revenue for the first nine months of 2026, representing a 7.9% increase at constant exchange rates and scope.

### What is Virbac SA's full-year 2026 revenue growth outlook?

The company expects full-year 2026 revenue growth to reach the upper end of its 5.5% to 7.5% range at constant exchange rates and scope.

### What profitability margin is Virbac SA targeting for 2026?

Virbac SA expects an adjusted recurring operating income margin of around 17% at constant exchange rates and scope for 2026.